The NKT cell ligand αgalactosylceramide suppresses allergic airway inflammation by induction of a Th1 response.
dc.contributor.author | Knothe, S | |
dc.contributor.author | Mutschler, V | |
dc.contributor.author | Rochlitzer, S | |
dc.contributor.author | Winkler, C | |
dc.contributor.author | Ebensen, T | |
dc.contributor.author | Guzman, C A | |
dc.contributor.author | Hohlfeld, J | |
dc.contributor.author | Braun, A | |
dc.contributor.author | Muller, M | |
dc.date.accessioned | 2011-07-01T13:53:14Z | |
dc.date.available | 2011-07-01T13:53:14Z | |
dc.date.issued | 2011-06-06 | |
dc.identifier.citation | The NKT cell ligand αgalactosylceramide suppresses allergic airway inflammation by induction of a Th1 response. 2011, 29 (25):4249-55 Vaccine | en |
dc.identifier.issn | 1873-2518 | |
dc.identifier.pmid | 21463684 | |
dc.identifier.doi | 10.1016/j.vaccine.2011.03.068 | |
dc.identifier.uri | http://hdl.handle.net/10033/135059 | |
dc.description.abstract | One experimental approach for the treatment of allergic reactions is the stimulation of immunoregulatory NKT cells with the synthetic glycolipid αgalactosylceramide. For a first evaluation of the immunomodulatory potential of αGalCerMPEG a human in vitro allergy model was exploited. Acting as an adjuvant, the glycolipid induced an enhanced Th1-biased allergen-specific immune response of autologous lymphocytes. In a mouse model of allergic airway inflammation, αGalCerMPEG-activated NKT cells promoted a cytokine environment in the spleen, leading to priming of Th1 cells. The shift towards a Th1-dominated allergen-specific immune response thus might mediate the abrogation of allergic airway inflammation and thereby might provide a valid option for therapeutic intervention. | |
dc.language.iso | en | en |
dc.title | The NKT cell ligand αgalactosylceramide suppresses allergic airway inflammation by induction of a Th1 response. | en |
dc.type | Article | en |
dc.contributor.department | Fraunhofer Institute for Toxicology and Experimental Medicine, Department of Immunology, Allergology and Immunotoxicology, Nikolai-Fuchs-Str. 1, 30625 Hannover, Germany. | en |
dc.identifier.journal | Vaccine | en |
refterms.dateFOA | 2018-06-13T07:24:30Z | |
html.description.abstract | One experimental approach for the treatment of allergic reactions is the stimulation of immunoregulatory NKT cells with the synthetic glycolipid αgalactosylceramide. For a first evaluation of the immunomodulatory potential of αGalCerMPEG a human in vitro allergy model was exploited. Acting as an adjuvant, the glycolipid induced an enhanced Th1-biased allergen-specific immune response of autologous lymphocytes. In a mouse model of allergic airway inflammation, αGalCerMPEG-activated NKT cells promoted a cytokine environment in the spleen, leading to priming of Th1 cells. The shift towards a Th1-dominated allergen-specific immune response thus might mediate the abrogation of allergic airway inflammation and thereby might provide a valid option for therapeutic intervention. |